-
Mashup Score: 0
Private equity firms make loads of money when their schemes succeed and lose very little when they fail.
Source: www.nytimes.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 2Private Equity in US Health Care - 1 year(s) ago
In this issue of JAMA Internal Medicine, Tyan and colleagues1 report that private equity (PE) involvement and acquisition of oncology clinics in the US has surged over the past 20 years. In several states, 1 of every 4 oncology clinics is owned by a PE company. It is no surprise, given the profit…
Source: jamanetwork.comCategories: Hem/Oncs, Latest HeadlinesTweet-
@iostrer @DGlaucomflecken @YaleMed @YaleIMed @JAMA_current @NicoleKuderer @mleapman @simon_p_kim @KevinTyan1 @Mirandalamm @ysingh_hopkins @janemzhu @healthecon_dan What to do? We need to stop incentivizing buy-outs with tax loopholes, FFS billing schema; increase federal scrutiny of mergers, acquisitions; enhance our understanding of the impact of PE ownership (greater transparency, urgent research) https://t.co/7Bst6rP7gQ https://t.co/z60rfB32lA
-
-
Mashup Score: 0
Holding Medical Professional Society Scientific Meetings Only in States That Protect Abortion Rights-Clinical and Ethical Considerations
Source: PubMedCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 4Health & Veritas | Yale Insights - 1 year(s) ago
Howard Forman and Harlan Krumholz, two Yale physician-professors, discuss the latest news and ideas in healthcare and seek out the truth amid the noise. Health & Veritas is produced with the Yale School of Management and the Yale School of Public Health.
Source: insights.som.yale.eduCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0Defining Adequate Representation and Setting Enrollment Targets for Clinical Trial Diversity - 1 year(s) ago
This Editorial discusses the existing policy efforts in the US for ensuring adequate racial and ethnic diversity in clinical trials, identifies barriers to consistency and acceptable representation, and suggests measures to address them.
Source: jamanetwork.comCategories: Hem/Oncs, Latest HeadlinesTweet-
** NEW @JAMAOnc editorial on #cancer trial diversity w/rising 🌟 @TanveeVarma & @millerbioethics: We show the *definition* of adequate representation has profound impact on accrual goals. Need clear guidance & comprehensive strategy to ➡️ #healthequity https://t.co/DDGCcj0Af0 https://t.co/NOxFX2vOVr https://t.co/WGwN3OLRSQ
-
-
Mashup Score: 3How Jimmy Carter boosted a life-saving cancer drug - 1 year(s) ago
A dire health threat to the former president in 2015 put the spotlight on a pathbreaking immune therapy.
Source: Washington PostCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 2Association Between Age and Survival Trends in Advanced Non–Small Cell Lung Cancer After Immunotherapy Adoption - 1 year(s) ago
This cohort study evaluates trends in survival after immune checkpoint inhibitor therapy in patients with advanced non–small cell lung cancer by age.
Source: jamanetwork.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 1Holding Medical Professional Society Scientific Meetings Only in States That Protect Abortion Rights - 1 year(s) ago
This Viewpoint suggests that professional societies should continue to advocate for equitable access for patients to all necessary medical care including abortion care.
Source: jamanetwork.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0
North Carolina has not yet expanded Medicaid under the ACA, but the state’s legislature announced in early 2023 that they had reached an agreement on the issue, and Medicaid expansion is expected to be in place in North Carolina by 2024. North Carolina’s transition to Medicaid managed care became effective July 1 2021.
Source: healthinsurance.orgCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 2Sign the Petition - 1 year(s) ago
Move Medical Conferences Out of States Without Full Access to Reproductive Care
Source: Change.orgCategories: Hem/Oncs, Latest HeadlinesTweet
@iostrer @DGlaucomflecken @YaleMed @YaleIMed @JAMA_current @NicoleKuderer @mleapman @simon_p_kim @KevinTyan1 @Mirandalamm @ysingh_hopkins @janemzhu @healthecon_dan In the context of increasing concerns about private equity overall; should our #healthcare infrastructure be leading the charge to sell out to PE? (5/n) https://t.co/fzNSMeuoqo